Remtolumab |
Katalog-Nr.GC72471 |
Remtolumab (ABT-122) ist ein Immunglobulin mit zwei variablen Domänen, das sowohl den Tumornekrosefaktor α (TNFα) als auch IL-17A neutralisiert.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1791410-27-9
Sample solution is provided at 25 µL, 10mM.
References:
[1]. Havnaer A, et al. Systemic therapies in psoriasis: an update on newly approved and pipeline biologics and oral treatments. Cutis. 2019 Aug;104(2S):17-20.
[2]. Khatri A, et al. Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. Clin Pharmacokinet. 2018 May;57(5):613-623.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *